TG
Thomas J Garrity
Director

Thomas J Garrity insider trades: Antares Pharma (ATRS) stock buys and sales

Director, Antares Pharma Last trade Mar 11, 2021 35 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2011
3
Companies
last trade 2021

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Thomas reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 11, 2021ATRS↓ Sell$214K
Feb 11, 2021ATRS↓ Sell$231K
Jan 11, 2021ATRS↓ Sell$284K
Dec 9, 2019ATRS↓ Sell$183K
May 1, 2019ATRS↓ Sell$80K
Oct 3, 2017ATRS↓ Sell$105K
Mar 31, 2017ATRS↓ Sell$87K
Mar 18, 2016ATRS↑ Buy$22K
Aug 11, 2014ATRS↑ Buy$10K
May 31, 2013ATRS↓ Sell$53K
Aug 20, 2012ATRS↓ Sell$124K
Mar 21, 2011AIS↑ Buy$16K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Thomas J Garrity's insider trades

Thomas J Garrity is a director at Antares Pharma (ATRS). Since Mar 21, 2011, Thomas has reported 3 open-market purchases worth $47K and 9 sales worth $1.4M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (19 filings), option exercises (10 filings), shares withheld for taxes (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ATRS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.